(NASDAQ: EOLS) Evolus's forecast annual revenue growth rate of 20.17% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.89%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.86%.
Evolus's revenue in 2025 is $277,941,000.On average, 3 Wall Street analysts forecast EOLS's revenue for 2025 to be $19,333,566,143, with the lowest EOLS revenue forecast at $19,154,646,274, and the highest EOLS revenue forecast at $19,569,926,664. On average, 3 Wall Street analysts forecast EOLS's revenue for 2026 to be $24,220,549,549, with the lowest EOLS revenue forecast at $23,047,414,790, and the highest EOLS revenue forecast at $24,925,232,503.
In 2027, EOLS is forecast to generate $31,619,526,516 in revenue, with the lowest revenue forecast at $28,267,528,103 and the highest revenue forecast at $34,227,642,610.